Den 29 augusti offentliggjorde Nanologica att bolaget avser att genomföra en fullt garanterad företrädesemission av units om ca 99,4 MSEK. I intervjun berättar vd Andreas Bhagwani mer om emissionen och bakgrunden till den.
FINANCIAL SUMMARY Net sales for the second quarter amounted to SEK 2,174 thousand (672) and for the half-year to SEK 7,211 thousand (1,026) Operating loss for the quarter amounted to SEK -9,832 thousand (-13,312) and for the half-year to SEK -25,163 thousand (-24,032) Loss before tax for the quarter amounted to SEK -11,126 thousand (-14,671) and for the half-year to SEK -27,860 thousand (-26,764) Earnings per share before and after dilution were SEK -0.25 (-0.41)
Nanologica has received an order for the company’s silica-based purification media NLAB Saga® from a customer in China who has previously evaluated the product. The value amounts to approximately SEK 2 million. The customer is a pharmaceutical manufacturer that has evaluated NLAB Saga® on a small scale and has now placed an order for production. “In China, we see a very strong activity in the GLP-1 analogue segment as a result of the patent for
Nanologica has now approved a number of normal-sized batches from the large-scale production of the company’s silica for preparative chromatography, NLAB Saga®. Scaling up to large-scale production of silica at the contract manufacturer Sterling Pharma Solutions has been fraught with several challenges such as loss of material, which has previously been communicated. Although a couple of challenges remain, the company has now for the first time completed several large production batches in a row, which
Watch the presentation via the link: CEO Andreas Bhagwani presents at Redeye Diabetes Event – 23 May 2024
